Registered title, quoted from ClinicalTrials.gov
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07487519, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Archival FFPE tumor tissue (≤6 months old, ≤2 years max) for PD-L1 testing; fresh biopsy acceptable if archival tissue is unavailable or inadequate.
Inclusion criterion 7
Phase II: Unresectable locally advanced, recurrent, or metastatic TNBC with no prior systemic anti-cancer therapy for this stage (palliative radiotherapy to metastases allowed; neoadjuvant/adjuvant therapy permitted if completed ≥6 months before recurrence/metastasis).
Inclusion criterion 5
Second primary malignancy within 2 years before randomization (except cured carcinoma in situ or stage I tumors).
Exclusion criterion 2
Phase I: Recurrent or metastatic TNBC after ≥1 prior line of standard systemic therapy.
Inclusion criterion 4
Washout: ≥3 weeks (or 5 half-lives, whichever is shorter) after major surgery, radiotherapy (except palliative bone RT), chemotherapy, targeted therapy, or immunotherapy; ≥1 week after minor surgery or anti-tumor TCM. All treatment-related AEs resolved to CTCAE v6.0 Grade ≤1 (stable Grade 2 peripheral neuropathy and alopecia exempted).
Inclusion criterion 8
Prior grade ≥3 immune-related adverse event during immunotherapy.
Exclusion criterion 3
ECOG PS 0-1, assessed ≤7 days before randomization.
Inclusion criterion 9
At least one RECIST v1.1-measurable lesion documented within 4 weeks before randomization.
Inclusion criterion 6
Active HBV , HCV , or HBV/HCV co-infection.
Exclusion criterion 16
Pregnancy or lactation.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07487519, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary written informed consent obtained before any study procedures.
- Age ≥ 18 years at consent; no gender restriction.
- Histopathologically confirmed TNBC: ER < 1%, PR < 1%, HER2 IHC 0/1+/2+ with no FISH amplification.
- Phase I: Recurrent or metastatic TNBC after ≥1 prior line of standard systemic therapy.
- Phase II: Unresectable locally advanced, recurrent, or metastatic TNBC with no prior systemic anti-cancer therapy for this stage (palliative radiotherapy to metastases allowed; neoadjuvant/adjuvant therapy permitted if completed ≥6 months before recurrence/metastasis).
- At least one RECIST v1.1-measurable lesion documented within 4 weeks before randomization.
Note: Target lesions must not be in irradiated fields or the CNS. If only measurable lesion is irradiated, imaging must confirm progression post-radiotherapy.
- Archival FFPE tumor tissue (≤6 months old, ≤2 years max) for PD-L1 testing; fresh biopsy acceptable if archival tissue is unavailable or inadequate.
Note: Specimens must be non-irradiated FFPE blocks/slides with pathology report confirming malignancy and adequacy.
- Washout: ≥3 weeks (or 5 half-lives, whichever is shorter) after major surgery, radiotherapy (except palliative bone RT), chemotherapy, targeted therapy, or immunotherapy; ≥1 week after minor surgery or anti-tumor TCM. All treatment-related AEs resolved to CTCAE v6.0 Grade ≤1 (stable Grade 2 peripheral neuropathy and alopecia exempted).
- ECOG PS 0-1, assessed ≤7 days before randomization.
- Life expectancy >3 months.
- Adequate hematologic, hepatic, and renal function per labs ≤7 days before randomization.
Exclusion Criteria:
- Prior topoisomerase I-targeting therapy (e.g., irinotecan, topotecan, or ADCs).
- Second primary malignancy within 2 years before randomization (except cured carcinoma in situ or stage I tumors).
- Prior grade ≥3 immune-related adverse event during immunotherapy.
- Uncontrolled, recurrent malignant pleural, pericardial, or ascitic effusions requiring repeated drainage.
- Active CNS metastases, spinal cord compression, or carcinomatous meningitis.
- Clinically significant pulmonary impairment.
- Uncontrolled cardiovascular or cerebrovascular disease .
- Active systemic infection requiring IV antibiotics within 2 weeks before randomization.
- Moderate or strong CYP2D6/CYP3A inhibitor or inducer use within 2 weeks before randomization.
- Systemic corticosteroids (>10 mg/day prednisone equivalent) or other immunosuppressants within 2 weeks before randomization .
- Active or suspected autoimmune disease .
- Live or attenuated live vaccine within 4 weeks before randomization.
- Hypersensitivity to mAbs, large-molecule biologics, or drug formulation excipients.
- Active pulmonary tuberculosis.
- Known immunodeficiency.
- Active HBV , HCV , or HBV/HCV co-infection.
- Pregnancy or lactation.
- Participation in another interventional trial within 30 days before consent .
- Any condition posing unacceptable safety risk or interfering with study conduct per investigator judgment.
Quoted from ClinicalTrials.gov, NCT07487519, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07487519, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.